CDMO News
CELLforCURE by SEQENS Partners with Galapagos to Manufacture CD19 CAR-T Therapy
CELLforCURE by SEQENS, a CDMO specialising in advanced therapy medicinal products (ATMPs), has announced a partnership with Galapagos NV to support clinical manufacturing of its CD19 CAR T-cell therapy candidate, GLPG5101. The therapy is currently being evaluated for multiple relapsed
19 June 2025
Stay ahead of trends and best practices
